[Hankyung] Top 1 CRO, C&R Research announced to increase the global revenue share to 30% within 6 years
“At the end of last year, we established overseas subsidiaries in the United States and Thailand. We aim to increase this year’s revenue by more than 25% by enhancing our global competitiveness.” said Moon-Tae Yoon, CEO of C&R Research, in an interview with Hankyung Business newspaper on the 14th Jan. He further stated, “We will increase the current global revenue share, which is currently less than 10%, to 30% by 2030.”
C&R Research, founded in 1997 as a contract research organization (CRO), went public on the KOSDAQ market in December 2021 through a merger with NH SPAC 17.
C&R Research is the leading CRO in Korea, with experience in conducting over 1800 clinical trials and employing over 500 specialized employees, including doctors, pharmacists, and nurses.
